Last edition
News about "enfortumab vedotin"
AstraZeneca's Imfinzi Combo Gets US Priority Review for MIBC
AstraZeneca’s Imfinzi and enfortumab vedotin combination has received US FDA Priority Review based on positive Phase 3 VOLGA results in muscle-invasive bladder cancer.
Enfortumab Vedotin | 28/09/2026 | By News Bureau
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Enfortumab Vedotin | 15/05/2026 | By News Bureau | 142
KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC
KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.
Enfortumab Vedotin | 18/12/2025 | By News Bureau | 269
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy